{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T22:29:04Z","timestamp":1790980144165,"version":"4.1.0"},"reference-count":94,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T00:00:00Z","timestamp":1767052800000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100007380","name":"Fondation de l'Avenir pour la Recherche M\u00e9dicale Appliqu\u00e9e","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007380","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neuroinflammation"],"DOI":"10.1186\/s12974-025-03625-x","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T05:23:54Z","timestamp":1763961834000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Inhibition of p38\u03b1 MAPK increases short-term astrocyte reactivity: the exploratory VIP trial in early Alzheimer\u2019s disease"],"prefix":"10.1186","volume":"22","author":[{"given":"Dominique","family":"Gouilly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Da-Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agathe","family":"Vrillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Pistono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Goubeaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsa","family":"Bertrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanne","family":"Germain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nad\u00e9ra","family":"Ainaoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Bras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Catala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9lanie","family":"Planton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9atrice","family":"Lemesle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Hitzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Sophie","family":"Salabert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonor","family":"Nogueira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Mouton-Liger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00e9borah","family":"M\u00e9ligne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Jasse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Rafiq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamine","family":"Sarton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stein","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Alam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Paquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clovis","family":"Tauber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Thalamas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Payoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice","family":"P\u00e9ran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00e9mie","family":"Pariente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,24]]},"reference":[{"key":"3625_CR1","doi-asserted-by":"publisher","unstructured":"Hampel H, Caraci F, Cuello AC, Caruso G, Nistic\u00f2 R, Corbo M, et al. A path toward precision medicine for neuroinflammatory mechanisms in Alzheimer\u2019s disease. Front Immunol. 2020;11:456. https:\/\/doi.org\/10.3389\/fimmu.2020.00456.","DOI":"10.3389\/fimmu.2020.00456"},{"key":"3625_CR2","doi-asserted-by":"publisher","unstructured":"Meyer PF, Tremblay-Mercier J, Leoutsakos J, Madjar C, Lafaille-Maignan M\u00c9, Savard M, et al. INTREPAD: a randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease. Neurology. 2019. https:\/\/doi.org\/10.1212\/WNL.0000000000007232.","DOI":"10.1212\/WNL.0000000000007232"},{"issue":"6","key":"3625_CR3","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1038\/sj.npp.1300690","volume":"30","author":"LJ Thal","year":"2005","unstructured":"Thal LJ, Ferris SH, Kirby L, Block GA, Lines CR, Yuen E, et al. A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology. 2005;30(6):1204\u201315.","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"3625_CR4","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/s41582-019-0307-9","volume":"16","author":"E Gyengesi","year":"2020","unstructured":"Gyengesi E, M\u00fcnch G. In search of an anti-inflammatory drug for Alzheimer disease. Nat Rev Neurol. 2020;16(3):131\u20132.","journal-title":"Nat Rev Neurol"},{"key":"3625_CR5","doi-asserted-by":"publisher","unstructured":"Morgan DG, Mielke MM. Knowledge gaps in Alzheimer\u2019s disease immune biomarker research. Alzheimers Dement. 2021;17(12):2030-42. https:\/\/doi.org\/10.1002\/alz.12342.","DOI":"10.1002\/alz.12342"},{"issue":"6","key":"3625_CR6","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/s43587-024-00630-2","volume":"4","author":"M Sarazin","year":"2024","unstructured":"Sarazin M, Lagarde J, El Haddad I, de Souza LC, Bellier B, Potier MC, et al. The path to next-generation disease-modifying immunomodulatory combination therapies in Alzheimer\u2019s disease. Nat Aging. 2024;4(6):761\u201370.","journal-title":"Nat Aging"},{"issue":"1","key":"3625_CR7","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/s12974-024-03163-y","volume":"21","author":"S Lista","year":"2024","unstructured":"Lista S, Imbimbo BP, Grasso M, Fidilio A, Emanuele E, Minoretti P, et al. Tracking neuroinflammatory biomarkers in Alzheimer\u2019s disease: a strategy for individualized therapeutic approaches? J Neuroinflammation. 2024;21(1):187.","journal-title":"J Neuroinflammation"},{"issue":"7","key":"3625_CR8","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1038\/s41591-023-02380-x","volume":"29","author":"B Bellaver","year":"2023","unstructured":"Bellaver B, Povala G, Ferreira PCL, Ferrari-Souza JP, Leffa DT, Lussier FZ, et al. Astrocyte reactivity influences amyloid-\u03b2 effects on tau pathology in preclinical Alzheimer\u2019s disease. Nat Med. 2023;29(7):1775\u201381.","journal-title":"Nat Med"},{"key":"3625_CR9","doi-asserted-by":"publisher","unstructured":"Heneka MT, van der Flier WM, Jessen F, Hoozemanns J, Thal DR, Boche D, et al. Neuroinflammation in Alzheimer disease. Nat Rev Immunol. 2025;25(5):321-52. https:\/\/doi.org\/10.1038\/s41577-024-01104-7.","DOI":"10.1038\/s41577-024-01104-7"},{"issue":"3","key":"3625_CR10","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/s41582-020-00435-y","volume":"17","author":"F Leng","year":"2021","unstructured":"Leng F, Edison P. Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here? Nat Rev Neurol. 2021;17(3):157\u201372.","journal-title":"Nat Rev Neurol"},{"issue":"4","key":"3625_CR11","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1093\/brain\/aww017","volume":"139","author":"L Hamelin","year":"2016","unstructured":"Hamelin L, Lagarde J, Doroth\u00e9e G, Leroy C, Labit M, Comley RA, et al. Early and protective microglial activation in Alzheimer\u2019s disease: a prospective study using 18 F-DPA-714 PET imaging. Brain. 2016;139(4):1252\u201364.","journal-title":"Brain"},{"key":"3625_CR12","doi-asserted-by":"crossref","unstructured":"Ismail R, Parbo P, Madsen LS, Hansen AK, Hansen KV, Schaldemose JL, et al. The relationships between neuroinflammation, beta-amyloid and tau deposition in Alzheimer\u2019s disease: a longitudinal PET study. J Neuroinflammation. 2020;17(1):151.","DOI":"10.1186\/s12974-020-01820-6"},{"key":"3625_CR13","doi-asserted-by":"crossref","unstructured":"Hamelin L, Lagarde J, Doroth\u00e9e G, Potier MC, Corlier F, Kuhnast B, et al. Distinct dynamic profiles of microglial activation are associated with progression of Alzheimer\u2019s disease. Brain. 2018;141(6):1855\u201370.","DOI":"10.1093\/brain\/awy079"},{"issue":"2012","key":"3625_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2012\/649079","volume":"25","author":"SAL Corr\u00eaa","year":"2012","unstructured":"Corr\u00eaa SAL, Eales KL. The role of p38 MAPK and its substrates in neuronal plasticity and neurodegenerative disease. J Signal Transduct. 2012;25(2012):1\u201312.","journal-title":"J Signal Transduct"},{"issue":"3","key":"3625_CR15","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.neuropharm.2009.11.010","volume":"58","author":"L Munoz","year":"2010","unstructured":"Munoz L, Ammit AJ. Targeting p38 MAPK pathway for the treatment of Alzheimer\u2019s disease. Neuropharmacology. 2010;58(3):561\u20138.","journal-title":"Neuropharmacology"},{"issue":"8","key":"3625_CR16","first-page":"1287","volume":"22","author":"JK Lee","year":"2017","unstructured":"Lee JK, Kim NJ. Recent advances in the inhibition of p38 MAPK as a potential strategy for the treatment of Alzheimer\u2019s disease. Mol Basel Switz. 2017;22(8):1287.","journal-title":"Mol Basel Switz"},{"issue":"2","key":"3625_CR17","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.neuron.2024.10.029","volume":"113","author":"P Naderi Yeganeh","year":"2025","unstructured":"Naderi Yeganeh P, Kwak SS, Jorfi M, Koler K, Kalatturu T, von Maydell D, et al. Integrative pathway analysis across humans and 3D cellular models identifies the p38 MAPK-MK2 axis as a therapeutic target for Alzheimer\u2019s disease. Neuron. 2025;113(2):205-224.e8.","journal-title":"Neuron"},{"issue":"3","key":"3625_CR18","first-page":"13","volume":"1","author":"AD Bachstetter","year":"2010","unstructured":"Bachstetter AD, Eldik LJV. The p38 MAP kinase family as regulators of proinflammatory cytokine production in degenerative diseases of the CNS. Aging Dis. 2010;1(3):13.","journal-title":"Aging Dis"},{"key":"3625_CR19","doi-asserted-by":"crossref","unstructured":"Kaminska B, Gozdz A, Zawadzka M, Ellert-Miklaszewska A, Lipko M. MAPK signal transduction underlying brain inflammation and gliosis as therapeutic target. Anat Rec Hoboken NJ 2007. 2009;292(12):1902\u201313.","DOI":"10.1002\/ar.21047"},{"issue":"6","key":"3625_CR20","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1007\/s10787-021-00889-6","volume":"29","author":"R Dhapola","year":"2021","unstructured":"Dhapola R, Hota SS, Sarma P, Bhattacharyya A, Medhi B, Reddy DH. Recent advances in molecular pathways and therapeutic implications targeting neuroinflammation for Alzheimer\u2019s disease. Inflammopharmacology. 2021;29(6):1669\u201381.","journal-title":"Inflammopharmacology"},{"issue":"12","key":"3625_CR21","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1038\/ng.2802","volume":"45","author":"JC Lambert","year":"2013","unstructured":"Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer\u2019s disease. Nat Genet. 2013;45(12):1452\u20138.","journal-title":"Nat Genet"},{"issue":"15","key":"3625_CR22","doi-asserted-by":"publisher","first-page":"10140","DOI":"10.1074\/jbc.274.15.10140","volume":"274","author":"P Pandey","year":"1999","unstructured":"Pandey P, Avraham S, Kumar S, Nakazawa A, Place A, Ghanem L, et al. Activation of p38 mitogen-activated protein kinase by PYK2\/related adhesion focal tyrosine kinase-dependent mechanism. J Biol Chem. 1999;274(15):10140\u20134.","journal-title":"J Biol Chem"},{"issue":"1","key":"3625_CR23","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s43587-023-00550-7","volume":"4","author":"BM Tijms","year":"2024","unstructured":"Tijms BM, Vromen EM, Mjaavatten O, Holstege H, Reus LM, van der Lee S, et al. Cerebrospinal fluid proteomics in patients with Alzheimer\u2019s disease reveals five molecular subtypes with distinct genetic risk profiles. Nat Aging. 2024;4(1):33\u201347.","journal-title":"Nat Aging"},{"key":"3625_CR24","doi-asserted-by":"crossref","unstructured":"Walker KA, Chen J, Shi L, Yang Y, Fornage M, Zhou L, et al. Proteomics analysis of plasma from middle-aged adults identifies protein markers of dementia risk in later life. Sci Transl Med. 2023;15(705):eadf5681.","DOI":"10.1126\/scitranslmed.adf5681"},{"issue":"4","key":"3625_CR25","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70171","volume":"21","author":"I Pola","year":"2025","unstructured":"Pola I, Ashton NJ, Ant\u00f4nio De Bastiani M, Brum WS, Rahmouni N, Tan K, et al. Exploring inflammation-related protein expression and its relationship with TSPO PET in Alzheimer\u2019s disease. Alzheimers Dement. 2025;21(4):e70171.","journal-title":"Alzheimers Dement"},{"issue":"2","key":"3625_CR26","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/s41593-021-00999-y","volume":"25","author":"ECB Johnson","year":"2022","unstructured":"Johnson ECB, Carter EK, Dammer EB, Duong DM, Gerasimov ES, Liu Y, et al. Large-scale deep multi-layer analysis of Alzheimer\u2019s disease brain reveals strong proteomic disease-related changes not observed at the RNA level. Nat Neurosci. 2022;25(2):213\u201325.","journal-title":"Nat Neurosci"},{"issue":"1","key":"3625_CR27","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s13195-021-00843-2","volume":"13","author":"ND Prins","year":"2021","unstructured":"Prins ND, Harrison JE, Chu HM, Blackburn K, Alam JJ, Scheltens P, et al. A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer\u2019s disease. Alzheimers Res Ther. 2021;13(1):106.","journal-title":"Alzheimers Res Ther"},{"issue":"6","key":"3625_CR28","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/S1474-4422(14)70090-0","volume":"13","author":"B Dubois","year":"2014","unstructured":"Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al. Advancing research diagnostic criteria for Alzheimer\u2019s disease: the IWG-2 criteria. Lancet Neurol. 2014;13(6):614\u201329.","journal-title":"Lancet Neurol"},{"issue":"4","key":"3625_CR29","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1002\/acn3.549","volume":"5","author":"P Scheltens","year":"2018","unstructured":"Scheltens P, Prins N, Lammertsma A, Yaqub M, Gouw A, Wink AM, et al. An exploratory clinical study of p38\u03b1 kinase inhibition in Alzheimer\u2019s disease. Ann Clin Transl Neurol. 2018;5(4):464\u201373.","journal-title":"Ann Clin Transl Neurol"},{"key":"3625_CR30","doi-asserted-by":"publisher","first-page":"1189278","DOI":"10.3389\/fneur.2023.1189278","volume":"14","author":"D Gouilly","year":"2023","unstructured":"Gouilly D, Salabert AS, Bertrand E, Goubeaud M, Catala H, Germain J, et al. Clinical heterogeneity of neuro-inflammatory PET profiles in early Alzheimer\u2019s disease. Front Neurol. 2023;14:1189278.","journal-title":"Front Neurol"},{"issue":"43","key":"3625_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.nicl.2024.103626","volume":"31","author":"D Gouilly","year":"2024","unstructured":"Gouilly D, Vrillon A, Bertrand E, Goubeaud M, Catala H, Germain J, et al. Translocator protein (TSPO) genotype does not change cerebrospinal fluid levels of glial activation, axonal and synaptic damage markers in early Alzheimer\u2019s disease. NeuroImage Clin. 2024;31(43):103626.","journal-title":"NeuroImage Clin"},{"issue":"6","key":"3625_CR32","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/nbt.1641","volume":"28","author":"DM Rissin","year":"2010","unstructured":"Rissin DM, Kan CW, Campbell TG, Howes SC, Fournier DR, Song L, et al. Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations. Nat Biotechnol. 2010;28(6):595\u20139.","journal-title":"Nat Biotechnol"},{"issue":"2","key":"3625_CR33","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1161\/01.STR.0000049766.26453.E9","volume":"34","author":"P Kapeller","year":"2003","unstructured":"Kapeller P, Barber R, Vermeulen RJ, Ad\u00e8r H, Scheltens P, Freidl W, et al. Visual rating of age-related white matter changes on magnetic resonance imaging: scale comparison, interrater agreement, and correlations with quantitative measurements. Stroke. 2003;34(2):441\u20135.","journal-title":"Stroke"},{"issue":"2","key":"3625_CR34","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1161\/STROKEAHA.117.016990","volume":"49","author":"SM Greenberg","year":"2018","unstructured":"Greenberg SM, Charidimou A. Diagnosis of cerebral amyloid angiopathy: evolution of the Boston criteria. Stroke. 2018;49(2):491\u20137.","journal-title":"Stroke"},{"key":"3625_CR35","doi-asserted-by":"crossref","unstructured":"Coup\u00e9 P, Mansencal B, Cl\u00e9ment M, Giraud R, Denis de Senneville B, Ta VT, et al. AssemblyNet: a large ensemble of CNNs for 3D whole brain MRI segmentation. NeuroImage. 2020;219:117026.","DOI":"10.1016\/j.neuroimage.2020.117026"},{"issue":"1","key":"3625_CR36","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1007\/s00259-020-05166-2","volume":"49","author":"E Nutma","year":"2021","unstructured":"Nutma E, Ceyz\u00e9riat K, Amor S, Tsartsalis S, Millet P, Owen DR, et al. Cellular sources of TSPO expression in healthy and diseased brain. Eur J Nucl Med Mol Imaging. 2021;49(1):146\u201363.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"3625_CR37","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s00259-021-05309-z","volume":"49","author":"J Schubert","year":"2021","unstructured":"Schubert J, Tonietto M, Turkheimer F, Zanotti-Fregonara P, Veronese M. Supervised clustering for TSPO PET imaging. Eur J Nucl Med Mol Imaging. 2021;49(1):257\u201368.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"3625_CR38","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1093\/brain\/awae045","volume":"147","author":"B Sarton","year":"2024","unstructured":"Sarton B, Tauber C, Fridman E, P\u00e9ran P, Riu B, Vinour H, et al. Neuroimmune activation is associated with neurological outcome in anoxic and traumatic coma. Brain J Neurol. 2024;147(4):1321\u201330.","journal-title":"Brain J Neurol"},{"issue":"2","key":"3625_CR39","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1111\/j..2002.384.doc.x","volume":"10","author":"GA Lancaster","year":"2004","unstructured":"Lancaster GA, Dodd S, Williamson PR. Design and analysis of pilot studies: recommendations for good practice. J Eval Clin Pract. 2004;10(2):307\u201312.","journal-title":"J Eval Clin Pract"},{"issue":"1","key":"3625_CR40","doi-asserted-by":"publisher","first-page":"447","DOI":"10.3233\/JAD-201584","volume":"82","author":"A Pistono","year":"2021","unstructured":"Pistono A, Senoussi M, Guerrier L, Rafiq M, Gim\u00e9no M, P\u00e9ran P, et al. Language network connectivity increases in early Alzheimer\u2019s disease. J Alzheimers Dis. 2021;82(1):447\u201360.","journal-title":"J Alzheimers Dis"},{"issue":"85","key":"3625_CR41","first-page":"2825","volume":"12","author":"F Pedregosa","year":"2011","unstructured":"Pedregosa F, Varoquaux G, Gramfort A, Michel V, Thirion B, Grisel O, et al. Scikit-learn: machine learning in python. J Mach Learn Res. 2011;12(85):2825\u201330.","journal-title":"J Mach Learn Res"},{"issue":"5","key":"3625_CR42","doi-asserted-by":"publisher","first-page":"707","DOI":"10.2967\/jnumed.114.149443","volume":"56","author":"Z Fan","year":"2015","unstructured":"Fan Z, Harold D, Pasqualetti G, Williams J, Brooks DJ, Edison P. Can studies of neuroinflammation in a TSPO genetic subgroup (HAB or MAB) be applied to the entire AD cohort? J Nucl Med. 2015;56(5):707\u201313.","journal-title":"J Nucl Med"},{"key":"3625_CR43","doi-asserted-by":"crossref","unstructured":"Ewers M, Franzmeier N, Su\u00e1rez-Calvet M, Morenas-Rodriguez E, Caballero MAA, Kleinberger G, et al. Increased soluble TREM2 in cerebrospinal fluid is associated with reduced cognitive and clinical decline in Alzheimer\u2019s disease. Sci Transl Med. 2019;11(507):eaav6221.","DOI":"10.1126\/scitranslmed.aav6221"},{"issue":"12","key":"3625_CR44","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1038\/s43587-022-00310-z","volume":"2","author":"JB Pereira","year":"2022","unstructured":"Pereira JB, Janelidze S, Strandberg O, Whelan CD, Zetterberg H, Blennow K, et al. Microglial activation protects against accumulation of tau aggregates in nondemented individuals with underlying Alzheimer\u2019s disease pathology. Nat Aging. 2022;2(12):1138\u201344.","journal-title":"Nat Aging"},{"issue":"6","key":"3625_CR45","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/1750-1326-6-84","volume":"20","author":"B Xing","year":"2011","unstructured":"Xing B, Bachstetter AD, Van Eldik LJ. Microglial p38\u03b1 MAPK is critical for LPS-induced neuron degeneration, through a mechanism involving TNF\u03b1. Mol Neurodegener. 2011;20(6):84.","journal-title":"Mol Neurodegener"},{"issue":"4","key":"3625_CR46","doi-asserted-by":"publisher","first-page":"7405","DOI":"10.1038\/srep07405","volume":"12","author":"U Lo","year":"2014","unstructured":"Lo U, Selvaraj V, Plane JM, Chechneva OV, Otsu K, Deng W. p38\u03b1 (MAPK14) critically regulates the immunological response and the production of specific cytokines and chemokines in astrocytes. Sci Rep. 2014;12(4):7405.","journal-title":"Sci Rep"},{"key":"3625_CR47","doi-asserted-by":"crossref","unstructured":"Kreisl WC, Lyoo CH, Liow JS, Wei M, Snow J, Page E, et al. 11C-PBR28 binding to translocator protein increases with progression of Alzheimer\u2019s disease. Neurobiol Aging. 2016;44:53\u201361.","DOI":"10.1016\/j.neurobiolaging.2016.04.011"},{"key":"3625_CR48","doi-asserted-by":"crossref","unstructured":"Benedet AL, Mil\u00e0-Alom\u00e0 M, Vrillon A, Ashton NJ, Pascoal TA, Lussier F, et al. Differences between plasma and cerebrospinal fluid glial fibrillary acidic protein levels across the Alzheimer disease continuum. JAMA Neurol. 2021;78(12):1471\u201383.","DOI":"10.1001\/jamaneurol.2021.3671"},{"issue":"12","key":"3625_CR49","doi-asserted-by":"publisher","first-page":"5672","DOI":"10.1002\/alz.13367","volume":"19","author":"HT Cronj\u00e9","year":"2023","unstructured":"Cronj\u00e9 HT, Liu X, Odden MC, Moseholm KF, Seshadri S, Satizabal CL, et al. Serum NfL and GFAP are associated with incident dementia and dementia mortality in older adults: the cardiovascular health study. Alzheimers Dement. 2023;19(12):5672\u201380.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"3625_CR50","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/alz.13450","volume":"20","author":"W Pelkmans","year":"2024","unstructured":"Pelkmans W, Shekari M, Brugulat-Serrat A, S\u00e1nchez-Benavides G, Minguill\u00f3n C, Fauria K, et al. Astrocyte biomarkers GFAP and YKL-40 mediate early Alzheimer\u2019s disease progression. Alzheimers Dement. 2024;20(1):483\u201393.","journal-title":"Alzheimers Dement"},{"issue":"12","key":"3625_CR51","doi-asserted-by":"publisher","first-page":"4094","DOI":"10.1093\/brain\/awae211","volume":"147","author":"DE Peretti","year":"2024","unstructured":"Peretti DE, Boccalini C, Ribaldi F, Scheffler M, Marizzoni M, Ashton NJ, et al. Association of glial fibrillary acid protein, Alzheimer\u2019s disease pathology and cognitive decline. Brain J Neurol. 2024;147(12):4094\u2013104.","journal-title":"Brain J Neurol"},{"key":"3625_CR52","doi-asserted-by":"crossref","unstructured":"Wang X, Shi Z, Qiu Y, Sun D, Zhou H. Peripheral GFAP and NfL as early biomarkers for dementia: longitudinal insights from the UK Biobank. BMC Med. 2024;22(1):192.","DOI":"10.1186\/s12916-024-03418-8"},{"key":"3625_CR53","doi-asserted-by":"crossref","unstructured":"Warmenhoven N, S\u00e1nchez-Benavides G, Gonz\u00e1lez-Escalante A, Mil\u00e0-Alom\u00e0 M, Shekari M, L\u00f3pez-Martos D, et al. CSF glial biomarkers are associated with cognition in individuals at risk of Alzheimer\u2019s disease. Alzheimers Dement J Alzheimers Assoc. 2024;20(9):5819\u201332.","DOI":"10.1002\/alz.13862"},{"issue":"11","key":"3625_CR54","doi-asserted-by":"publisher","first-page":"4781","DOI":"10.1038\/s41380-022-01716-2","volume":"27","author":"JP Ferrari-Souza","year":"2022","unstructured":"Ferrari-Souza JP, Ferreira PCL, Bellaver B, Tissot C, Wang YT, Leffa DT, et al. Astrocyte biomarker signatures of amyloid-\u03b2 and tau pathologies in Alzheimer\u2019s disease. Mol Psychiatry. 2022;27(11):4781\u20139.","journal-title":"Mol Psychiatry"},{"issue":"2","key":"3625_CR55","doi-asserted-by":"publisher","first-page":"385","DOI":"10.3233\/JAD-141506","volume":"44","author":"J Wang","year":"2015","unstructured":"Wang J, Tan L, Wang HF, Tan CC, Meng XF, Wang C, et al. Anti-inflammatory drugs and risk of Alzheimer\u2019s disease: an updated systematic review and meta-analysis. J Alzheimers Dis. 2015;44(2):385\u201396.","journal-title":"J Alzheimers Dis"},{"key":"3625_CR56","unstructured":"Gevorkyan H, Jhee S, Park L, et al. Abstract OC20, 9th Clinical Trials on Alzheimer\u2019s Disease (CTAD), San Diego, CA, USA, December 8\u201310, 2016. Conference proceedings. J Prev Alzheimers Dis. Volume 3, Supplement 1."},{"issue":"1","key":"3625_CR57","doi-asserted-by":"publisher","first-page":"5308","DOI":"10.1038\/s41467-022-32944-3","volume":"13","author":"Y Jiang","year":"2022","unstructured":"Jiang Y, Alam JJ, Gomperts SN, Maruff P, Lemstra AW, Germann UA, et al. Preclinical and randomized clinical evaluation of the p38\u03b1 kinase inhibitor neflamapimod for basal forebrain cholinergic degeneration. Nat Commun. 2022;13(1):5308.","journal-title":"Nat Commun"},{"issue":"17","key":"3625_CR58","doi-asserted-by":"publisher","first-page":"e1708","DOI":"10.1212\/WNL.0000000000207755","volume":"101","author":"JJ Alam","year":"2023","unstructured":"Alam JJ, Maruff P, Doctrow SR, Chu HM, Conway J, Gomperts SN, et al. Association of plasma phosphorylated Tau with the response to neflamapimod treatment in patients with dementia with Lewy bodies. Neurology. 2023;101(17):e1708\u201317.","journal-title":"Neurology"},{"key":"3625_CR59","doi-asserted-by":"crossref","unstructured":"Alam J, Teunissen C. Abstract LB25, 17th Clinical Trials on Alzheimer\u2019s Disease (CTAD) Madrid, Spain, October 29 - November 1, 2024: conference proceedings. J Prev Alzheimers Dis. 2025;12(1, Supplement):100043.","DOI":"10.1016\/j.tjpad.2024.100043"},{"issue":"12","key":"3625_CR60","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1093\/brain\/awy265","volume":"141","author":"A Surendranathan","year":"2018","unstructured":"Surendranathan A, Su L, Mak E, Passamonti L, Hong YT, Arnold R, et al. Early microglial activation and peripheral inflammation in dementia with Lewy bodies. Brain J Neurol. 2018;141(12):3415\u201327.","journal-title":"Brain J Neurol"},{"issue":"168","key":"3625_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2022.105698","volume":"15","author":"J Amin","year":"2022","unstructured":"Amin J, Erskine D, Donaghy PC, Surendranathan A, Swann P, Kunicki AP, et al. Inflammation in dementia with Lewy bodies. Neurobiol Dis. 2022;15(168):105698.","journal-title":"Neurobiol Dis"},{"issue":"12","key":"3625_CR62","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1016\/j.parkreldis.2015.10.009","volume":"21","author":"A Surendranathan","year":"2015","unstructured":"Surendranathan A, Rowe JB, O\u2019Brien JT. Neuroinflammation in Lewy body dementia. Parkinsonism Relat Disord. 2015;21(12):1398\u2013406.","journal-title":"Parkinsonism Relat Disord"},{"issue":"7","key":"3625_CR63","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/s41582-023-00822-1","volume":"19","author":"R Patani","year":"2023","unstructured":"Patani R, Hardingham GE, Liddelow SA. Functional roles of reactive astrocytes in neuroinflammation and neurodegeneration. Nat Rev Neurol. 2023;19(7):395\u2013409.","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"3625_CR64","volume":"12","author":"TH Edwin","year":"2020","unstructured":"Edwin TH, Henjum K, Nilsson LNG, Watne LO, Persson K, Eldholm RS, et al. A high cerebrospinal fluid soluble TREM2 level is associated with slow clinical progression of Alzheimer\u2019s disease. Alzheimers Dement Diagn Assess Dis Monit. 2020;12(1):e12128.","journal-title":"Alzheimers Dement Diagn Assess Dis Monit"},{"issue":"12","key":"3625_CR65","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/j.jalz.2016.06.005","volume":"12","author":"JD Gispert","year":"2016","unstructured":"Gispert JD, Su\u00e1rez-Calvet M, Mont\u00e9 GC, Tucholka A, Falcon C, Rojas S, et al. Cerebrospinal fluid sTREM2 levels are associated with gray matter volume increases and reduced diffusivity in early Alzheimer\u2019s disease. Alzheimers Dement. 2016;12(12):1259\u201372.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"3625_CR66","doi-asserted-by":"publisher","first-page":"117","DOI":"10.3233\/JAD-220102","volume":"88","author":"F Leng","year":"2022","unstructured":"Leng F, Zhan Z, Sun Y, Liu F, Edison P, Sun Y, et al. Cerebrospinal fluid sTREM2 has paradoxical association with brain structural damage rate in early- and late-stage Alzheimer\u2019s disease. J Alzheimers Dis. 2022;88(1):117\u201326.","journal-title":"J Alzheimers Dis"},{"issue":"24","key":"3625_CR67","doi-asserted-by":"publisher","DOI":"10.1172\/JCI158708","volume":"132","author":"A Zhao","year":"2022","unstructured":"Zhao A, Jiao Y, Ye G, Kang W, Tan L, Li Y, et al. Soluble TREM2 levels associate with conversion from mild cognitive impairment to Alzheimer\u2019s disease. J Clin Invest. 2022;132(24):e158708.","journal-title":"J Clin Invest"},{"issue":"6","key":"3625_CR68","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1111\/ene.13583","volume":"25","author":"M Casati","year":"2018","unstructured":"Casati M, Ferri E, Gussago C, Mazzola P, Abbate C, Bellelli G, et al. Increased expression of TREM2 in peripheral cells from mild cognitive impairment patients who progress into Alzheimer\u2019s disease. Eur J Neurol. 2018;25(6):805\u201310.","journal-title":"Eur J Neurol"},{"issue":"5","key":"3625_CR69","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1002\/ana.26885","volume":"95","author":"G Lan","year":"2024","unstructured":"Lan G, Chen X, Yang J, Sun P, Cai Y, Li A, et al. Microglial reactivity correlates with presynaptic loss independent of \u03b2-amyloid and tau. Ann Neurol. 2024;95(5):917\u201328.","journal-title":"Ann Neurol"},{"issue":"1","key":"3625_CR70","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13024-020-00374-8","volume":"15","author":"LZ Ma","year":"2020","unstructured":"Ma LZ, Tan L, Bi YL, Shen XN, Xu W, Ma YH, et al. Dynamic changes of CSF sTREM2 in preclinical Alzheimer\u2019s disease: the CABLE study. Mol Neurodegener. 2020;15(1):25.","journal-title":"Mol Neurodegener"},{"key":"3625_CR71","doi-asserted-by":"crossref","unstructured":"Shue F, White LJ, Hendrix R, Ulrich J, Henson RL, Knight W, et al. CSF biomarkers of immune activation and Alzheimer\u2019s disease for predicting cognitive impairment risk in the elderly. Sci Adv. 2024;10(14):eadk3674.","DOI":"10.1126\/sciadv.adk3674"},{"issue":"5","key":"3625_CR72","doi-asserted-by":"publisher","first-page":"466","DOI":"10.15252\/emmm.201506123","volume":"8","author":"M Su\u00e1rez-Calvet","year":"2016","unstructured":"Su\u00e1rez-Calvet M, Kleinberger G, Araque Caballero M\u00c1, Brendel M, Rominger A, Alcolea D, et al. sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer\u2019s disease and associate with neuronal injury markers. EMBO Mol Med. 2016;8(5):466\u201376.","journal-title":"EMBO Mol Med"},{"issue":"1","key":"3625_CR73","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13024-018-0301-5","volume":"14","author":"M Su\u00e1rez-Calvet","year":"2019","unstructured":"Su\u00e1rez-Calvet M, Morenas-Rodr\u00edguez E, Kleinberger G, Schlepckow K, Araque Caballero M\u00c1, Franzmeier N, et al. Early increase of CSF sTREM2 in Alzheimer\u2019s disease is associated with tau related-neurodegeneration but not with amyloid-\u03b2 pathology. Mol Neurodegener. 2019;14(1):1.","journal-title":"Mol Neurodegener"},{"key":"3625_CR74","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.neurobiolaging.2022.06.013","volume":"118","author":"RL Winfree","year":"2022","unstructured":"Winfree RL, Dumitrescu L, Blennow K, Zetterberg H, Gifford KA, Pechman KR, et al. Biological correlates of elevated soluble TREM2 in cerebrospinal fluid. Neurobiol Aging. 2022;118:88\u201398.","journal-title":"Neurobiol Aging"},{"issue":"9","key":"3625_CR75","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1038\/s41591-021-01456-w","volume":"27","author":"TA Pascoal","year":"2021","unstructured":"Pascoal TA, Benedet AL, Ashton NJ, Kang MS, Therriault J, Chamoun M, et al. Microglial activation and tau propagate jointly across Braak stages. Nat Med. 2021;27(9):1592\u20139.","journal-title":"Nat Med"},{"issue":"1","key":"3625_CR76","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13024-019-0319-3","volume":"14","author":"JL Del-Aguila","year":"2019","unstructured":"Del-Aguila JL, Benitez BA, Li Z, Dube U, Mihindukulasuriya KA, Budde JP, et al. TREM2 brain transcript-specific studies in AD and TREM2 mutation carriers. Mol Neurodegener. 2019;14(1):18.","journal-title":"Mol Neurodegener"},{"issue":"11","key":"3625_CR77","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/S1474-4422(23)00247-8","volume":"22","author":"K Schlepckow","year":"2023","unstructured":"Schlepckow K, Morenas-Rodr\u00edguez E, Hong S, Haass C. Stimulation of TREM2 with agonistic antibodies-an emerging therapeutic option for Alzheimer\u2019s disease. Lancet Neurol. 2023;22(11):1048\u201360.","journal-title":"Lancet Neurol"},{"key":"3625_CR78","doi-asserted-by":"crossref","unstructured":"Denali Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights | Denali Therapeutics. Available from: https:\/\/investors.denalitherapeutics.com\/news-releases\/news-release-details\/denali-therapeutics-reports-second-quarter-2023-financial. Cited 2025 Feb 4.","DOI":"10.1016\/j.fopow.2023.08.020"},{"key":"3625_CR79","unstructured":"Alector Announces Results from AL002 INVOKE-2 phase 2 trial in individuals with early Alzheimer\u2019s disease and provides business update | Alector. Available from: https:\/\/investors.alector.com\/news-releases\/news-release-details\/alector-announces-results-al002-invoke-2-phase-2-trial\/. Cited 2025 Feb 4."},{"key":"3625_CR80","doi-asserted-by":"publisher","first-page":"1576020","DOI":"10.3389\/fnagi.2025.1576020","volume":"17","author":"YN Ma","year":"2025","unstructured":"Ma YN, Hu X, Karako K, Song P, Tang W, Xia Y. The potential and challenges of TREM2-targeted therapy in Alzheimer\u2019s disease: insights from the INVOKE-2 study. Front Aging Neurosci. 2025;17:1576020.","journal-title":"Front Aging Neurosci"},{"issue":"10","key":"3625_CR81","doi-asserted-by":"publisher","first-page":"3217","DOI":"10.1038\/s41591-025-03816-2","volume":"31","author":"M Colonna","year":"2025","unstructured":"Colonna M, Holtzman DM. Rethinking TREM2 as a target for Alzheimer\u2019s disease after the INVOKE-2 trial failure. Nat Med. 2025;31(10):3217\u20138.","journal-title":"Nat Med"},{"issue":"2","key":"3625_CR82","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1177\/0271678X17692599","volume":"38","author":"D Garc\u00eda-Lorenzo","year":"2018","unstructured":"Garc\u00eda-Lorenzo D, Lavisse S, Leroy C, Wimberley C, Bodini B, Remy P, et al. Validation of an automatic reference region extraction for the quantification of [18 F]DPA-714 in dynamic brain PET studies. J Cereb Blood Flow Metab. 2018;38(2):333\u201346.","journal-title":"J Cereb Blood Flow Metab"},{"issue":"1","key":"3625_CR83","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-016-0226-3","volume":"6","author":"A Nair","year":"2016","unstructured":"Nair A, Veronese M, Xu X, Curtis C, Turkheimer F, Howard R, et al. Test-retest analysis of a non-invasive method of quantifying [11C]-PBR28 binding in Alzheimer\u2019s disease. EJNMMI Res. 2016;6(1):72.","journal-title":"EJNMMI Res"},{"issue":"12","key":"3625_CR84","doi-asserted-by":"publisher","first-page":"3685","DOI":"10.1093\/brain\/awv288","volume":"138","author":"Z Fan","year":"2015","unstructured":"Fan Z, Okello AA, Brooks DJ, Edison P. Longitudinal influence of microglial activation and amyloid on neuronal function in Alzheimer\u2019s disease. Brain. 2015;138(12):3685\u201398.","journal-title":"Brain"},{"key":"3625_CR85","doi-asserted-by":"publisher","unstructured":"Fan Z, Brooks DJ, Okello A, Edison P. An early and late peak in microglial activation in Alzheimer\u2019s disease trajectory. Brain. 2017;140(3):792-803. https:\/\/doi.org\/10.1093\/brain\/aww349.","DOI":"10.1093\/brain\/aww349"},{"issue":"11","key":"3625_CR86","doi-asserted-by":"publisher","first-page":"8028","DOI":"10.1002\/alz.14298","volume":"20","author":"LS Madsen","year":"2024","unstructured":"Madsen LS, Ismail R, Parbo P, Kjeldsen PL, Schaldemose JL, Hansen KV, et al. Microglial responses partially mediate the effect of A\u03b2 on cognition in Alzheimer\u2019s disease. Alzheimers Dement. 2024;20(11):8028\u201337.","journal-title":"Alzheimers Dement"},{"issue":"3","key":"3625_CR87","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1002\/alz.12204","volume":"17","author":"C Van Hulle","year":"2021","unstructured":"Van Hulle C, Jonaitis EM, Betthauser TJ, Batrla R, Wild N, Kollmorgen G, et al. An examination of a novel multipanel of CSF biomarkers in the Alzheimer\u2019s disease clinical and pathological continuum. Alzheimers Dement. 2021;17(3):431\u201345.","journal-title":"Alzheimers Dement"},{"key":"3625_CR88","doi-asserted-by":"publisher","unstructured":"Gouilly D, Saint-Aubert L, Ribeiro MJ, Salabert AS, Tauber C, P\u00e9ran P, et al. Neuroinflammation PET imaging of the translocator protein (TSPO) in Alzheimer\u2019s disease: an update. Eur J Neurosci. 2022;55(5):1322-43. https:\/\/doi.org\/10.1111\/ejn.15613.","DOI":"10.1111\/ejn.15613"},{"issue":"1","key":"3625_CR89","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1186\/s12974-023-02869-9","volume":"20","author":"EF Garland","year":"2023","unstructured":"Garland EF, Dennett O, Lau LC, Chatelet DS, Bottlaender M, Nicoll JAR, et al. The mitochondrial protein TSPO in Alzheimer\u2019s disease: relation to the severity of AD pathology and the neuroinflammatory environment. J Neuroinflammation. 2023;20(1):186.","journal-title":"J Neuroinflammation"},{"issue":"1","key":"3625_CR90","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1007\/s00401-024-02822-x","volume":"148","author":"EF Garland","year":"2024","unstructured":"Garland EF, Antony H, Kulagowska L, Scott T, Rogien C, Bottlaender M, et al. The microglial translocator protein (TSPO) in Alzheimer\u2019s disease reflects a phagocytic phenotype. Acta Neuropathol (Berl). 2024;148(1):62.","journal-title":"Acta Neuropathol (Berl)"},{"key":"3625_CR91","doi-asserted-by":"publisher","unstructured":"Metaxas A, Thygesen C, Briting SRR, Landau AM, Darvesh S, Finsen B. Increased inflammation and unchanged density of Synaptic Vesicle Glycoprotein 2A (SV2A) in the postmortem frontal cortex of Alzheimer\u2019s disease patients. Front Cell Neurosci. 2019;13:538. https:\/\/doi.org\/10.3389\/fncel.2019.00538.","DOI":"10.3389\/fncel.2019.00538"},{"issue":"1","key":"3625_CR92","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12974-022-02383-4","volume":"19","author":"C Mu\u00f1oz-Castro","year":"2022","unstructured":"Mu\u00f1oz-Castro C, Noori A, Magdamo CG, Li Z, Marks JD, Frosch MP, et al. Cyclic multiplex fluorescent immunohistochemistry and machine learning reveal distinct states of astrocytes and microglia in normal aging and Alzheimer\u2019s disease. J Neuroinflammation. 2022;19(1):30.","journal-title":"J Neuroinflammation"},{"issue":"1","key":"3625_CR93","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1111\/bpa.12763","volume":"30","author":"Y Gui","year":"2020","unstructured":"Gui Y, Marks JD, Das S, Hyman BT, Serrano-Pozo A. Characterization of the 18 kDa translocator protein (TSPO) expression in post-mortem normal and Alzheimer\u2019s disease brains. Brain Pathol. 2020;30(1):151\u201364.","journal-title":"Brain Pathol"},{"issue":"1","key":"3625_CR94","doi-asserted-by":"publisher","first-page":"5247","DOI":"10.1038\/s41467-023-40937-z","volume":"14","author":"E Nutma","year":"2023","unstructured":"Nutma E, Fancy N, Weinert M, Tsartsalis S, Marzin MC, Muirhead RCJ, et al. Translocator protein is a marker of activated microglia in rodent models but not human neurodegenerative diseases. Nat Commun. 2023;14(1):5247.","journal-title":"Nat Commun"}],"container-title":["Journal of Neuroinflammation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-025-03625-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12974-025-03625-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-025-03625-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T03:01:59Z","timestamp":1767063719000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12974-025-03625-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,24]]},"references-count":94,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3625"],"URL":"https:\/\/doi.org\/10.1186\/s12974-025-03625-x","relation":{},"ISSN":["1742-2094"],"issn-type":[{"value":"1742-2094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,24]]},"assertion":[{"value":"18 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the French Ethics Committee \u201cComit\u00e9 de Protection des Personnes Sud-Est 1\u201d (reference number: 2017\u201378) and the French Drug Safety and Health Products Agency (reference number: MEDAECNAT-2018\u201301-0034). All the participants provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dominique Gouilly received research funding from the Fondation de l\u2019Avenir (Paris, France) for this study. Other authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"298"}}